Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Heart failure disease management programs: a cost-effectiveness analysis.

David C Chan1, Paul A Heidenreich, Milton C Weinstein

  • 1Brigham and Women's Hospital, Boston, MA 02115, USA. dcchan@partners.org

American Heart Journal
|January 25, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regulation of mitophagy by Fis1 and Fascin1-organized actin.

Current biology : CB·2026
Same author

RHOA regulates mitochondria-ER contact sites through modulation of the VAPB/PTPIP51 tether.

Nature communications·2025
Same author

Variation in Telehealth Use for Patients With Incident Atrial Fibrillation Across the Veterans Health Administration: Retrospective Cohort Study.

Journal of medical Internet research·2025
Same author

Subspecialization of Surgical Specialties in the US.

JAMA health forum·2025
Same author

Putative PINK1/Parkin activators lower the threshold for mitophagy by sensitizing cells to mitochondrial stress.

Science advances·2025
Same author

Geographic Variation in the Utilization of Cancer Care From Subspecialized Medical Oncologists in the United States, 2008 to 2020.

Annals of internal medicine·2025
Same journal

Stratified Medicine with Eplerenone for Myocardial Infarction or Injury and No obstructive Coronary Arteries: A Registry-Based Basket Trial.

American heart journal·2026
Same journal

Revised Lipid-Lowering Therapy Guidelines in a Nationally Representative Sample.

American heart journal·2026
Same journal

Cardiometabolic Health of Low- and Higher-Income Adults in the United States, 2009-2023.

American heart journal·2026
Same journal

Moving Beyond Technical Capability to Regulatory Integration for Digital Health Technology Devices-Brief Communication from the Cardiovascular Sciences Research Consortium.

American heart journal·2026
Same journal

THE SOCIETY OF CRITICAL CARE CARDIOLOGY - RATIONALE, BLUEPRINT, AND LESSONS LEARNED IN THE CREATION OF A NEW MULTIDISCIPLINARY PROFESSIONAL ORGANIZATION.

American heart journal·2026
Same journal

DOAC Score Among Patients Receiving Vitamin K Antagonists.

American heart journal·2026
See all related articles

Heart failure disease management is cost-effective for all patients, not just high-risk individuals. Expanding these programs to a wider patient group significantly increases life-years saved, improving overall health outcomes.

Area of Science:

  • Cardiology
  • Health Economics
  • Public Health

Background:

  • Heart failure (HF) disease management programs reduce hospitalizations and mortality.
  • Current guidelines restrict HF disease management to high-risk patients.
  • Limited studies exist on long-term effectiveness across all risk levels.

Purpose of the Study:

  • To evaluate the cost-effectiveness of HF disease management for patients across the entire risk spectrum.
  • To assess the impact of expanding HF disease management beyond high-risk populations.
  • To determine the incremental life expectancy and cost of universal HF disease management.

Main Methods:

  • Utilized a novel technique to analyze patient risk targeting in clinical trials based on hospitalization and mortality rates.

Related Experiment Videos

  • Employed a Markov model to calculate the cost-effectiveness of disease management across risk groups.
  • Conducted sensitivity analyses for long-term scenarios and reduced effectiveness in lower-risk patients.

    • Main Results:

    • Universal HF disease management yielded an incremental cost-effectiveness ratio of $9700 per life-year gained in the base case.
    • Extending coverage to all patients nearly quadrupled life-years saved compared to high-risk quintile coverage.
    • Probabilistic sensitivity analysis indicated 99.74% of ratios were below $50,000 per life-year gained.

    Conclusions:

    • HF disease management programs demonstrate long-term cost-effectiveness across all patient risk levels.
    • Broader enrollment of HF patients in disease management can significantly extend health gains.
    • Universal application of HF disease management is a valuable strategy for improving patient outcomes.